Open AccessSerum Irisin: Pathogenesis and Clinical Research in Cardiovascular Diseases
Author(s) -
Lütfü Aşkın,
Kader Eliz Üzel,
Okan Tanrıverdi,
Serdar Türkmen
Publication year - 2020
Publication title -
cardiovascular innovations and applications
Language(s) - English
Resource type - Journals
eISSN - 2009-8782
pISSN - 2009-8618
DOI - 10.15212/cvia.2019.0569
Subject(s) - myokine , insulin resistance , adipose tissue , endothelial dysfunction , homeostasis , endocrinology , medicine , inflammation , pathogenesis , skeletal muscle , glucose homeostasis , hormone , obesity , diabetes mellitus , metabolic syndrome , endocrine system , bioinformatics , biology
Recently, muscular function/dysfunction has gained importance in the maintenance of metabolic homeostasis in cardiovascular diseases. Skeletal muscle plays a vital role in coordinating the activity and metabolism of endocrine organs by secreting many myokines, especially irisin. Irisin is a polypeptide hormone consisting of 112 amino acids secreted into the blood from muscle and adipose tissues. Serum irisin levels are associated with cardiometabolic risk factors such as obesity and insulin resistance as defined by homeostatic model assessment. Irisin reduces endothelial damage by inhibiting inflammation and oxidative stress, thus playing a key role in maintaining endothelial cell function. Unsurprisingly, low irisin levels cause endothelial dysfunction and increase the incidence of atherosclerosis. We aimed to summarize the studies on this issue since we have not found any review in the literature on the role of serum irisin levels in the process of atherosclerosis and other cardiovascular events in cardiovascular diseases.